Legal & General Group Plc raised its position in BioTelemetry, Inc. (NASDAQ:BEAT) by 0.2% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 46,979 shares of the medical research company’s stock after buying an additional 107 shares during the period. Legal & General Group Plc owned approximately 0.17% of BioTelemetry worth $1,360,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. California Public Employees Retirement System boosted its stake in shares of BioTelemetry by 2.0% in the first quarter. California Public Employees Retirement System now owns 98,800 shares of the medical research company’s stock worth $2,860,000 after buying an additional 1,900 shares during the period. Teachers Advisors LLC boosted its stake in shares of BioTelemetry by 7.6% in the first quarter. Teachers Advisors LLC now owns 46,786 shares of the medical research company’s stock worth $1,354,000 after buying an additional 3,297 shares during the period. Wellington Management Group LLP boosted its stake in shares of BioTelemetry by 28.7% in the first quarter. Wellington Management Group LLP now owns 1,009,507 shares of the medical research company’s stock worth $29,225,000 after buying an additional 225,407 shares during the period. Principal Financial Group Inc. boosted its stake in shares of BioTelemetry by 4.0% in the first quarter. Principal Financial Group Inc. now owns 231,087 shares of the medical research company’s stock worth $6,690,000 after buying an additional 8,926 shares during the period. Finally, ClariVest Asset Management LLC boosted its stake in shares of BioTelemetry by 0.6% in the first quarter. ClariVest Asset Management LLC now owns 70,241 shares of the medical research company’s stock worth $2,033,000 after buying an additional 400 shares during the period. Institutional investors and hedge funds own 76.72% of the company’s stock.

BioTelemetry, Inc. (BEAT) traded down 0.14% during midday trading on Friday, hitting $35.70. 520,132 shares of the stock were exchanged. The company has a market cap of $1.16 billion, a PE ratio of 23.96 and a beta of 0.76. BioTelemetry, Inc. has a 12 month low of $15.25 and a 12 month high of $37.50. The firm’s 50 day moving average price is $34.26 and its 200 day moving average price is $29.69.

BioTelemetry (NASDAQ:BEAT) last posted its quarterly earnings data on Tuesday, August 8th. The medical research company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.21 by $0.02. The firm had revenue of $58.10 million during the quarter, compared to analyst estimates of $58.39 million. BioTelemetry had a net margin of 21.03% and a return on equity of 18.75%. BioTelemetry’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.20 EPS. On average, equities research analysts forecast that BioTelemetry, Inc. will post $0.99 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “BioTelemetry, Inc. (NASDAQ:BEAT) Shares Bought by Legal & General Group Plc” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/08/19/legal-general-group-plc-has-1-36-million-stake-in-biotelemetry-inc-nasdaqbeat-updated-updated-updated.html.

A number of brokerages have weighed in on BEAT. BidaskClub upgraded shares of BioTelemetry from a “buy” rating to a “strong-buy” rating in a report on Wednesday. Zacks Investment Research upgraded shares of BioTelemetry from a “hold” rating to a “strong-buy” rating and set a $39.00 price target on the stock in a report on Friday, August 11th. Sidoti reiterated a “buy” rating and set a $49.00 price target (up previously from $42.00) on shares of BioTelemetry in a report on Thursday, August 10th. Dougherty & Co increased their price target on shares of BioTelemetry from $37.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, August 9th. Finally, Benchmark Co. increased their price target on shares of BioTelemetry from $38.00 to $44.00 and gave the company a “buy” rating in a report on Wednesday, July 19th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. BioTelemetry presently has an average rating of “Buy” and an average price target of $44.40.

About BioTelemetry

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Institutional Ownership by Quarter for BioTelemetry (NASDAQ:BEAT)

Receive News & Stock Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related stocks with our FREE daily email newsletter.